Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation

Patent metadata

Field	Value
Publication number	US-9480775-B2
Application number	US-201514665820-A
Country	US
Kind code	B2
Filing date	Mar 23, 2015
Priority date	Mar 22, 2010
Publication date	Nov 1, 2016
Grant date	Nov 1, 2016

Abstract

Disclosed herein are cohesive soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and optionally including proteins. In one aspect, hyaluronic acid-based compositions described herein include zero-length cross-linked moieties and optionally at least one active agent. The present hyaluronic acid-based compositions have enhanced flow characteristics, hardness, and persistence compared to known hyaluronic acid-based compositions. Methods and processes of preparing such hyaluronic acid-based compositions are also provided.

First claim

What is claimed is:

1. A hydrogel composition for soft tissue augmentation, comprising:
a hyaluronic acid polymer crosslinked with collagen via a zero-length crosslinking agent;
wherein said hydrogel is formed by:
(a) reacting said hyaluronic acid polymer with said collagen via said zero-length cross-linking agent;
wherein said zero-length cross-linking agent is a carbodiimide;
thereby providing a crosslinked hyaluronic acid/collagen-based composition; and
(b) sterilizing the crosslinked hyaluronic acid/collagen-based composition using a gaseous agent or an irradiation source, wherein the irradiation source comprises ultraviolet light, visible light or microwaves.

2. The hydrogel composition of claim 1 , wherein said zero-length cross-linking agent is 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC).

3. The hydrogel composition according to claim 1 , wherein said zero-length cross-linking agent is reacted with said hyaluronic acid polymer and said collagen at neutral pH, wherein said neutral pH is between about 6.0 and about 8.0.

4. The hydrogel composition according to claim 3 , wherein said neutral pH is between about 6.5 and about 7.5.

5. The hydrogel composition according to claim 4 , wherein said neutral pH is about 7.0.

6. The hydrogel composition according to claim 1 , further comprising an active agent selected from the group consisting of an enzyme inhibitor, anesthetic agent, medicinal neurotoxin, antioxidant, anti-infective agent, anti-inflammatory agent, ultraviolet light blocking agent, dye, hormone, immunosuppressant, and combinations thereof.

7. The hydrogel composition according to claim 6 , wherein the active agent is an anesthetic agent.

8. The hydrogel composition according to claim 1 , wherein the hydrogel is sterilized using the gaseous agent.

9. The hydrogel composition according to claim 1 , wherein the hydrogel is sterilized using the irradiation source.

10. The hydrogel of claim 1 , having a hyaluronic acid concentration of about 15 mg/mL to about 80 mg/mL.

11. The hydrogel of claim 1 , having a hyaluronic acid concentration of about 15 mg/mL to about 30 mg/mL.

12. The hydrogel of claim 1 , having a hyaluronic acid concentration of about 26 mg/mL.

13. Previously presented) The hydrogel of claim 2 , wherein said zero-length cross-linking agent is reacted with said hyaluronic acid polymer and said collagen in the presence of N-hydroxysuccinimide (NHS).

14. The hydrogel composition according to claim 7 , wherein the anesthetic agent is lidocaine.

Assignees

• Allergan Inc

Inventors

• Guillen Karina Heredia
• Tezel Ahmet

Classifications

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P5/00

  Drugs for disorders of the endocrine system · CPC title

• A61P39/06

  Free radical scavengers or antioxidants · CPC title

• A61P31/00

  Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title